We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ginkgo Bioworks Holdings, Inc. (DNA) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest close session, Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) was up +1.06% at $16.14. The stock's change was more than the S&P 500's daily gain of 0.01%. On the other hand, the Dow registered a gain of 0.51%, and the technology-centric Nasdaq decreased by 0.28%.
Prior to today's trading, shares of the company had gained 36.73% outpaced the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83%.
Investors will be eagerly watching for the performance of Ginkgo Bioworks Holdings, Inc. in its upcoming earnings disclosure. In that report, analysts expect Ginkgo Bioworks Holdings, Inc. to post earnings of -$1.24 per share. This would mark a year-over-year decline of 14.81%. Meanwhile, the latest consensus estimate predicts the revenue to be $39 million, indicating a 56.2% decrease compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$5.27 per share and a revenue of $181 million, signifying shifts of +49.13% and -20.28%, respectively, from the last year.
Any recent changes to analyst estimates for Ginkgo Bioworks Holdings, Inc. should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Ginkgo Bioworks Holdings, Inc. presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 74, putting it in the top 30% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ginkgo Bioworks Holdings, Inc. (DNA) Outpaces Stock Market Gains: What You Should Know
In the latest close session, Ginkgo Bioworks Holdings, Inc. (DNA - Free Report) was up +1.06% at $16.14. The stock's change was more than the S&P 500's daily gain of 0.01%. On the other hand, the Dow registered a gain of 0.51%, and the technology-centric Nasdaq decreased by 0.28%.
Prior to today's trading, shares of the company had gained 36.73% outpaced the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83%.
Investors will be eagerly watching for the performance of Ginkgo Bioworks Holdings, Inc. in its upcoming earnings disclosure. In that report, analysts expect Ginkgo Bioworks Holdings, Inc. to post earnings of -$1.24 per share. This would mark a year-over-year decline of 14.81%. Meanwhile, the latest consensus estimate predicts the revenue to be $39 million, indicating a 56.2% decrease compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$5.27 per share and a revenue of $181 million, signifying shifts of +49.13% and -20.28%, respectively, from the last year.
Any recent changes to analyst estimates for Ginkgo Bioworks Holdings, Inc. should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Ginkgo Bioworks Holdings, Inc. presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 74, putting it in the top 30% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.